The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM D

OMB APPROVAL OMB Number: 3235-0076 Estimated average burden

4.00

hours per response:

Notice of Exempt Offering of Securities

1. Issuer's Identity			
-	Previous		
CIK (Filer ID Number)	Names	None	Entity Type
<u>0001479419</u>	Kala Pharma	ceuticals, Inc.	Corporation
Name of Issuer			Limited Partnership
KALA BIO, Inc.			Limited Liability Company
Jurisdiction of Incorporation/Orga	anization		General Partnership
DELAWARE			Business Trust
Year of Incorporation/Organization	on		Other (Specify)
Over Five Years Ago			
Within Last Five Years (Spec	cify Year)		
Yet to Be Formed			
2. Principal Place of Business a	and Contact Information		
Name of Issuer			
KALA BIO, Inc.			
Street Address 1		Street Address 2	
1167 MASSACHUSETTS AVENUI	E		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
ARLINGTON	MASSACHUSETTS	02476	781-996-5252
3. Related Persons			
Last Name	First Name		Middle Name
Iwicki	Mark		
Street Address 1	Street Address 2		
1167 Massachusetts Avenue			
City	State/Province/C	ountry	ZIP/PostalCode
Arlington	MASSACHUSET		02476
Relationship: Executive Office	cer 🚺 Director 🔲 Promo	ter	
Clarification of Response (if Nece	essary):		
Last Name	First Name		Middle Name
Bazemore	Todd		
Street Address 1	Street Address 2		
1167 Massachusetts Avenue			
City	State/Province/C	ountry	ZIP/PostalCode
Arlington	MASSACHUSETTS		02476
Relationship: Executive Office	cer Director Promo	ter	
Clarification of Response (if Nece	essary):		
Lost Name	First Name		Middle Neme
Last Name Brazzell	First Name Kim		Middle Name
Street Address 1	Street Address 2		
1167 Massachusetts Avenue	Street Address 2		
City	State/Province/C	ountry	ZIP/PostalCode
Arlington	MASSACHUSETT		02476
Relationship: Executive Office			<u></u>
Clarification of Response (if Nece			

Last Name	First Name	Middle Name	
Kharabi	Darius		
Street Address 1	Street Address 2		
1167 Massachusetts Avenue			
City	State/Province/Country	ZIP/PostalCode	
Arlington MASSACHUSETTS		02476	
Relationship: Executive Officer			
Clarification of Response (if Necessa	ary):		
	F: 4N	NOTE: NO	
Last Name	First Name	Middle Name	
Reumuth	Mary		
Street Address 1	Street Address 2		
1167 Massachusetts Avenue			
City	State/Province/Country	ZIP/PostalCode	
Arlington	MASSACHUSETTS	02476	
Relationship: Executive Officer	Director Promoter		
Clarification of Response (if Necessa	ary):		
Last Name	First Name	Middle Name	
Koven	Andrew	I.	
Street Address 1	Street Address 2		
1167 Massachusetts Avenue			
City	State/Province/Country	ZIP/PostalCode	
Arlington	MASSACHUSETTS	02476	
		02470	
Relationship: Executive Officer	Director Promoter		
Clarification of Response (if Necessa	ary):		
Last Name	First Name	Middle Name	
Perry	Gregory	D.	
Street Address 1	Street Address 2		
1167 Massachusetts Avenue			
City	State/Province/Country	ZIP/PostalCode	
Arlington	MASSACHUSETTS	02476	
Relationship: Executive Officer	☑ Director ☐ Promoter		
Clarification of Response (if Necessa	ary):		
Last Name	First Name	Middle Name	
Farid	Marjan		
Street Address 1	Street Address 2		
1167 Massachusetts Avenue	00017.184.1000 =		
City	State/Province/Country	ZIP/PostalCode	
Arlington	MASSACHUSETTS	02476	
Relationship: Executive Officer		02170	
Clarification of Response (if Necessa			
		Middle News	
Last Name	First Name	Middle Name	
Rosen	Howard	В.	
Street Address 1	Street Address 2		
1167 Massachusetts Avenue			
City	State/Province/Country	ZIP/PostalCode	
Arlington	MASSACHUSETTS	02476	
Relationship: Executive Officer	☑ Director ☐ Promoter		
Clarification of Response (if Necessa	ary):		
Last Name	First Name	Middle Name	
Myers	C.	Daniel	
Street Address 1	Street Address 2		

1167 Massachusetts Avenue City	State/Province/Country	ZIP/PostalCode
Arlington	MASSACHUSETTS	02476
Relationship: Executive Officer		32170
Clarification of Response (if Necessary):		
4. Industry Group		
Agriculture	Health Care	Retailing
Banking & Financial Services	Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology
Insurance	Hospitals & Physicial	
Investing Investment Banking	Pharmaceuticals	Telecommunications
Pooled Investment Fund		
Is the issuer registered as	Other Health Care	Other Technology
an investment company under	Manufacturing Real Estate	Travel
the Investment Company Act of 1940?	Commercial	Airlines & Airports
Yes No	Construction	Lodging & Conventions
Other Banking & Financial Servi		Tourism & Travel Services
Business Services	TETTO & Tillance	Other Travel
Energy	Residential	Other
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net Asset Valu	ue Range
No Revenues	No Aggregate Net As	sset Value
\$1 - \$1,000,000	\$1 - \$5,000,000	
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000	
\$5,000,001 - \$25,000,000 \$25,000,001 -	\$25,000,001 - \$50,00	
\$100,000,000	\$50,000,001 - \$100,0	000,000
Over \$100,000,000	Over \$100,000,000	
Decline to Disclose	Decline to Disclose	
Not Applicable	Not Applicable	
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)	
	Investment Compa	ny Act Section 3(c)
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)
Rule 506(b) Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)
		[] Section 3(c)(14)
	Section 3(c)(7)	
7. Type of Filing		
New Notice Date of First Sale 2024- Amendment	12-31 First Sale Yet to Occur	
8. Duration of Offering		

Does the Issuer intend this offering to last more than one year?	Yes No	
9. Type(s) of Securities Offered (select all that apply)		
Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant of Right to Acquire Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combinemerger, acquisition or exchange offer?	nation transaction, such as a Yes No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 US	D	
12. Sales Compensation		
Recipient	Recipient CRD Number V None	
(Associated) Broker or Dealer 🕡 None	(Associated) Broker or Dealer CRD Number 📝 None	
Street Address 1	Street Address 2	
City	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$10,749,667 USD or Indefinite Total Amount Sold \$10,749,667 USD Total Paragining to be Sold as \$0,000 or Indefinite		
Total Remaining to be Sold \$0 USD or Indefinite		
Clarification of Response (if Necessary):		
14. Investors		
enter the number of such non-accredited investors who alr	or may be sold to persons who do not qualify as accredited	6
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finder an estimate and check the box next to the amount.	rs fees expenses, if any. If the amount of an expenditure is no	t known, provide
Sales Commissions \$0 USD Estimate		
Finders' Fees \$0 USD Estimate		
Clarification of Response (if Necessary):		
16. Use of Proceeds		
Provide the amount of the gross proceeds of the offering that has be named as executive officers, directors or promoters in respon the box next to the amount.		
\$0 USD Estimate		
Clarification of Response (if Necessary):		
Signature and Submission		
Please verify the information you have entered and review to file this notice.	he Terms of Submission below before signing and clickin	g SUBMIT below

In submitting this notice, each issuer named above is:

Terms of Submission

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
KALA BIO, Inc.	/s/ Mary Reumuth	Mary Reumuth	Chief Financial Officer	2024-12-31

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D. States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.